Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
86%(12 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
1
7%
Ph phase_2
3
20%
Ph phase_3
11
73%

Phase Distribution

1

Early Stage

3

Mid Stage

11

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
1(6.7%)
Phase 2Efficacy & side effects
3(20.0%)
Phase 3Large-scale testing
11(73.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
93.3%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (6.7%)
Phase 23 (20.0%)
Phase 311 (73.3%)

Trials by Status

completed1493%
terminated17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT03456063Phase 3

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Completed
NCT03191786Phase 3

A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy

Completed
NCT02927301Phase 2

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Completed
NCT03125902Phase 3

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

Completed
NCT03197935Phase 3

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed
NCT02763579Phase 3

A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Completed
NCT03386721Phase 2

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Terminated
NCT02420821Phase 3

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Completed
NCT02813785Phase 3

A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy

Completed
NCT02425891Phase 3

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Completed
NCT02366143Phase 3

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT02367781Phase 3

A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Completed
NCT02431208Phase 1

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed
NCT01984242Phase 2

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Completed
NCT02788279Phase 3

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15